Welcome to the INA-RESPOND public website.
Current and expanding infectious disease profile in Indonesia warrants a sense of urgency and mandates that research be a priority to guide the management and prevention of disease to reduce morbidity and mortality. The purpose of Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) is to bring together clinical and academic medical institutions to develop a robust collaborative infectious disease research network.
The INA-RESPOND network is inviting all interested Indonesian government and private hospitals to participate in our HIV study entitled, “A Prospective Observational Cohort Study On HIV Infection And Risk Related Coinfections/Comorbidities In Indonesia” (INA-PROACTIVE). Send an email to ina104sitesupport@ina-respond.net or call our head office at +62 21 4287 9189 (Mr. Caleb/Ikhsan or Ms. Lois) for
On July 21-22, 2017, INA-RESPOND Secretariat invited four active TRIPOD sites to attend the first TRIPOD interim analysis meeting. The four active sites are RSUP Sanglah Denpasar, Bali (site 520); RSUP dr. Kariadi, Semarang (site 560); RSUD Soetomo, Surabaya (site 570); and RSUP dr. Sardjito, Yogyakarta (site 580). The Principal Investigator (PI) or Co-PI and
The Indonesia Research Partnership on Infectious Disease (INA-RESPOND) is going to hold its second Steering Committee meeting of 2017 at J.W Marriott, Jakarta on August 2. A Mini Symposium will be held the following day (August 3), which will be attended by approximately 125 representatives from health research networks, government institutions, and private health companies.
Department of Health and Human Services | National Institutes of Health Policy and Procedures THE INTRAMURAL NIH HUMAN RESEARCH PROTECTION PROGRAM (HRPP) The NIH’s mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability (for
To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.
To determine the causes of community-acquired sepsis and severe sepsis in adults and pediatrics across Southeast Asia.
To estimate the proportion of MDR TB amongst treatment naïve new treatment naïve and previously treated cases.
